Edition:
United States

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

18.30USD
1:54pm EST
Change (% chg)

$0.28 (+1.55%)
Prev Close
$18.02
Open
$18.00
Day's High
$18.40
Day's Low
$17.99
Volume
257,831
Avg. Vol
647,302
52-wk High
$22.38
52-wk Low
$5.36

Chart for

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 2.19
Market Cap(Mil.): $1,697.62
Shares Outstanding(Mil.): 94.21
Dividend: --
Yield (%): --

Financials

  ARWR.OQ Industry Sector
P/E (TTM): -- 85.34 35.95
EPS (TTM): -0.35 -- --
ROI: -20.72 10.06 12.64
ROE: -24.06 10.28 13.82

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion, sending its shares surging 20 percent.

Oct 04 2018

UPDATE 1-J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

* Shares gain as much as 20 pct premarket (Adds share movement and comment from analyst, CEO)

Oct 04 2018

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

Oct 4 Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.

Oct 04 2018

Earnings vs. Estimates